How Android is Transforming the Medical Devices Market, infographic

Android-based medical devices have recently seen a big surge in adoption

How the Android platform is influencing healthcare using new technologies and apps.

This infographic explains the key trends in the Android OS medical devices market and where embedded healthcare technology is headed.

Medical-Apps-Market infographic
This infographic explains the key trends in the Android OS medical devices market and where embedded healthcare technology is headed.
Sources and more information

Management of females exposed to DES-type drugs ; 1977 recommendations

Vaginal and cervical cancers and other abnormalities associated with exposure in utero to diethylstilbestrol and related synthetic hormones

woman-at-hospital
1977 study and recommendations about vaginal and cervical cancers and other abnormalities associated with exposure in utero to diethylstilbestrol and related synthetic hormones. all you’ve been through.

1977 Study Abstract

All asymptomatic girls who wore exposed to diethylstilbestrol in utero should receive a thorough pelvic examination at menarche or if they have reached 14 years of age. Younger girls should be examined if they develop abnormal bleeding or discharge. Whenever prenatal exposure is probable and theme are symptoms of discharge, further investigation is imperative, regardless of the patient’s age. This investigation should not be concluded until it is certain that no lesion is present.

Before the examination is undertaken, the entire procedure should be thoroughly discussed with the patient (and her mother on father if she is a minor).

The examination should include inspection and palpation, Papanicolaou smear (cervix and vagina), and an iodine staining test of the entire cervix and vagina. Abnormal areas, including those that do not stain with iodine, should be biopsied.  This procedure can be performed in the physician’s office with small biopsy instruments and without significant discomfort.

For the very young patient who has symptoms that require investigation, anesthesia may occasionally be required be fore an examination. A small speculum permits adequate visualization of the vagina without undue discomfort in younger patients.

With asymptomatic females, if adequate examination is not possible at the initial visit, vaginal tampons should be used for a few months to allow an adequate examination later without discomfort. Colposcopy is a useful adjunct to this examination, but it is not essential. Utilizing its low power magnification to examine the vagina and cervix, the physician can identify areas of glandular tissue (adenosis) in the vagina on on the cervix. This identification permits directed rather than “blind” biopsies. When used in con junction with the iodine staining test and selected biopsy, colposcopy permits precise recording of observed abnormalities and their appraisal at fixed intervals.

The patient exposed to DES-type drugs should be followed on a regular basis. After a normal initial examination, annual pelvic examinations with cervical and vaginal cytology and iodine staining are probably adequate. If any abnormalities are noted during the initial evaluation, more frequent follow-up examinations are suggested (every 3 to 6 months, depending on the severity of the findings).

Locally destructive measures such as cauterization, cryosurgery, or excision can be utilized if atypical changes such as marked squamous dysplasia on carcinoma in situ of the vagina or cervix are found on biopsy.

Sources and more information
  • Vaginal and cervical cancers and other abnormalities associated with exposure in utero to diethylstilbestrol and related synthetic hormones, Cancer Research, 1977 Apr.
More DES DiEthylStilbestrol Resources

2015 International Summit on Human Gene Editing

Scientists debate ethics of human gene editing at international summit

International Summit on Human Gene Editing
Deep and disturbing questions’ surrounding diseases and designer babies examined at summit as experiments get closer to altering human heredity.

A major component of the National Academy of Sciences and the National Academy of Medicine’s Human Gene-Editing Initiative is an international summit to take place December 1-3 in Washington, D.C. Co-hosted with the Chinese Academy of Sciences and the U.K.’s Royal Society, the summit will convene experts from around the world to discuss the scientific, ethical, and governance issues associated with human gene-editing research.

More information

Drugs prescribed by Doctors and Big Pharma Tactics…

Doctors and Pharma Ties…

big-pharma cartoon
If you aren’t familiar yet with the shenanigans we’ve uncovered by Big Pharma to get away with literally murder all these years, here’s a great example of how hilariously obvious their tactics are when you see them.
Health cartoons
Related posts

Diethylstilbestrol: risks of malignant disease and congenital malformations

US National Library of Medicine, Canadian Medical Association, 1979

image of malignant-disease
DiEthylStilbestrol usage review buttress the need for adequate and rigorous research into the use of drugs in pregnancy and ensure that they do more good than harm before being introduced for consumption.

1979 Study Abstract

In 1951 a prospective double-blind study was begun at the University of Chicago to evaluate the usefulness of diethylstilbestrol in the protection of pregnancy. The women involved, the controls and all the offspring are being carefully followed up. Preliminary long-term follow-up data, collected to the end of 1977, have been reviewed by a task force of the Department of National Health and Welfare’s special advisory committee on reproductive physiology.

The Chicago study and others have demonstrated that the female offspring of women given diethylstilbestrol during pregnancy are at an increased risk for a variety of benign abnormalities of the genital tract. In addition, the very infrequent occurrence of carcinoma of the vagina or cervix in such individuals is well documented.

It is now also evident that prenatal exposure of males to diethylstilbestrol is associated with a low frequency of various detectable anatomic and functional changes in the reproductive tract. The abnormalities observed include epididymal cysts, hypoplastic testes, induration of the testicular capsule, and some impairment of spermatogenesis, sperm maturation and accessory gland secretion; malignant lesions have not been reported.

Sources and more information
  • Diethylstilbestrol: risks of malignant disease and congenital malformations, Canadian Medical Association, NCBI PMCID: PMC1704227, 1979 Jun 23.
  • Full text PDF, CMA JOURNAL/JUNE 23, 1979/VOL. 120.
More DES DiEthylStilbestrol Resources

Deadly prescription opioid epidemic must be stopped

By Dr. David Juurlink, Professor and head, Division of Clinical Pharmacology, University of Toronto

This post content is published by Troy Media – an editorial content provider to over 1,800 print and online media outlets within Canada.

An estimated 10,000 to 20,000 Canadians have died from opioids since 1995, and an untold number now suffer from addiction. Image Javier Maria Trigo.

By Dr. David Juurlink, Professor and head, Division of Clinical Pharmacology, University of Toronto

Dear Minister Jane Philpott,

Congratulations on your appointment as minister of Health. As an experienced physician, you bring valuable perspective to the post. While there are many contentious matters before you, including a new health accord, physician-assisted dying and marijuana legalization, few could be more pressing than the prescription opioid epidemic. It is an issue all but ignored by your predecessors but it is the greatest drug safety crisis Canada has ever faced.

When you returned to Canada in 1998 after nearly a decade of practice in Africa, you witnessed the seeds of this epidemic being sown, with strong painkillers like OxyContin prescribed liberally for chronic back pain, arthritis and fibromyalgia. You heard experts say these drugs worked well for chronic pain, that the risk of addiction was low, and that doctors who resisted prescribing them were “opiophobic.” Perhaps you even began prescribing opioids for chronic pain, as did I and thousands of our colleagues, unaware that what we had been told was untrue.

It’s clear now that we were objects in an elaborate marketing effort. Cloaked as it was in the virtues of compassion and beneficence, it was a remarkable success – until, that is, we considered our patients. Today, doctors’ offices are inundated with people who have been harmed more than helped by these drugs. Thousands more are dead. No demographic has been spared. And yet the marketing continues, with pain specialists and advocacy groups opposing moves to curtail opioid prescribing, their efforts financed by the very companies that make these drugs. These forces, coupled with the societal expectation that pain be medicated, threaten every community in this country.

An estimated 10,000 to 20,000 Canadians have died from opioids since 1995, and an untold number now suffer from addiction. The federal government must take the lead in dealing with this crisis, rather than offloading responsibility to the provinces. I propose several concrete measures to that end. Some are squarely within your purview; others will require provincial co-operation.

We must quantify the toll of the epidemic. In the United States, more than 16,000 people die of opioids each year; remarkably, there are no corresponding data for Canada. We can’t fix what we don’t even measure. The Public Health Agency of Canada should work with provinces to develop mechanisms to quantify opioid-related deaths. These numbers should be public.

Prescription monitoring programs should connect pharmacies in real time, in part to identify the small but important subset of patients seeking prescriptions for misuse or resale. These systems can also identify physicians whose prescribing falls afoul of good practice or, in some instances, the law. In an era when teens on different continents play video games in real time, it’s absurd that pharmacies in the same town operate in isolation.

Some measures involve specific drugs. Eliminate non-prescription codeine products from Canadian pharmacies. These are poor analgesics prone to abuse at high doses, resulting in deaths from acetaminophen and ASA toxicity. Revoke approval for generic OxyContin tablets, which are easily crushed and disproportionately benefit the dealers who sell them. The popular painkiller tramadol is increasingly abused and should be reclassified as a controlled substance, as its pharmacology demands and as Health Canada contemplated in 2007 before being lobbied by Purdue Pharma. Finally, treatment with fentanyl – an especially dangerous drug – should be restricted to patients willing to return used patches for new ones.

People with opioid addiction need more support and less marginalization. They require greater access to addiction specialists and medications like buprenorphine, along with supervised injection sites for those who choose this path. These save lives, as does the antidote naloxone, which should be freely available to anyone who wants it. Health Canada’s review of naloxone, inexcusably glacial, must be accelerated.

Finally, the government should introduce legislation akin to America’s Sunshine Act, illuminating the financial relationships between pharmaceutical companies and doctors, specialty organizations and advocacy groups. The money here flows in one direction, its sole purpose to increase drug sales. This initiative, sure to be opposed, will necessitate provincial co-operation.

Some of these suggestions are more easily implemented than others, but all warrant your consideration. With more than a hundred Canadians dying every month, there is no time to waste.

© 2015 Distributed by Troy Media

STILBOESTROL 5 mg Tablets by British Drug Houses Ltd

Diethylstilbestrol or DES was sold under many names

image of a Stilboestrol-5-mg bottle
Diethylstilbestrol or DES was sold under many names. Image credit © Science Museum.

Diethylstilbestrol or DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

Many different companies manufactured and marketed this drug under more than 200 different brand names.

This glass bottle of Stilboestrol tablets 5 mg was manufactured by:
The British Drug Houses Ltd,
London, Greater London, England,
United Kingdom.

DES drugs pictures
More DES DiEthylStilbestrol Resources